Vertex, NHS trade barbs over CF pricing

NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) failed to resolve a stalemate over Orkambi lumacaftor/ivacaftor at their latest meeting to discuss reimbursement of the cystic fibrosis drug.

While the two parties released terse statements Thursday in the wake of a meeting

Read the full 418 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE